News

News Archive

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting

Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting

FLORENCE, Italy and NEW YORK, May 23, 2023 – The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and...
Fair Play Menarini International Award, here are the dates of the 2024 edition

Fair Play Menarini International Award, here are the dates of the 2024 edition

FLORENCE, May 14th 2024 – Preparations are in full swing for the upcoming Fair Play Menarini International Award, the event that, every year, celebrates athletes who have become...
VERONESE, A RIOT OF COLOURS The new Menarini Art Volume, dedicated to the great painter, showcased in Turin

VERONESE, A RIOT OF COLOURS The new Menarini Art Volume, dedicated to the great painter, showcased in Turin

Turin, 6 May 2024 - The latest volume of the Menarini Group’s prestigious art series, showcased on Sunday 5 May at Palazzo Madama in Turin, takes us back to the pomp of the...
4 in 10 elderly excluded on the basis of their age from getting the best health-care, globally. Carta of Florence, the first manifesto against health ageism, released

4 in 10 elderly excluded on the basis of their age from getting the best health-care, globally. Carta of Florence, the first manifesto against health ageism, released

FLORENCE, Italy - 9th April, 2024 - Fondazione Menarini, in the forefront of the fight against discrimination in health-care of the elderly, has contributed to the development of the...
Le Volpi Rosse Menarini conquistano il secondo posto all'Eurocup 3

Le Volpi Rosse Menarini conquistano il secondo posto all'Eurocup 3

Content available only in italian language

New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection

New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection

Malvern, PA, Parsippany, NJ, and Florence, Italy - February 20, 2024 – Venatorx Pharmaceuticals,  Melinta Therapeutics LLC (“Melinta”), and Menarini Group today...
12

Select a Year from the Archive

Our values

Our values

Everyday we put our values into action. 4 values, which have given life to Menarini and have shaped its history.

Read More

Our values

Go to Follow our blog

Follow our blog

Discover our stories from all over the world

Read More